By employing a different methodological approach for detection of aPL, such as TLC immunostaining, as well as new antigenic targets of APS, such as vimentin/cardiolipin complex, it may be possible to detect aPL/cofactors in about two-thirds of SN-APS patients with thrombosis or pregnancy morbidity [50]. This evidence concerns the gene VIM and autoimmune polyendocrinopathy.